(NASDAQ: SPRO) Spero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 54.31%.
Spero Therapeutics's earnings in 2025 is -$53,601,000.On average, 1 Wall Street analyst forecast SPRO's earnings for 2025 to be -$44,457,428, with the lowest SPRO earnings forecast at -$44,457,428, and the highest SPRO earnings forecast at -$44,457,428.
In 2026, SPRO is forecast to generate -$41,643,667 in earnings, with the lowest earnings forecast at -$41,643,667 and the highest earnings forecast at -$41,643,667.